Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A US Physician Perspective

Bertram L. Kasiske

Research output: Contribution to journalEditorialpeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)354-357
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume50
Issue number3
DOIs
StatePublished - Sep 2007

Bibliographical note

Funding Information:
Support: None. Financial Disclosure: During the past 3 years, Dr Kasiske received research support from Bristol-Meyers Squibb and a Merck/Schering-Plough Joint Venture. He has also received honoria and/or consulting fees from Wyeth, Astellas, Pfizer, and Novartis, all for work related to kidney transplantation. None of the above companies have financial interests in erythropoiesis-stimulating agents. Dr. Kasiske is a paid medical director of a dialysis facility owned and operated by DaVita, Inc.

Cite this